TEVA PHARMACEUTICAL-SP ADR (TEVA) Stock Fundamental Analysis
NYSE:TEVA - New York Stock Exchange, Inc. - US8816242098 - ADR - Currency: USD
Taking everything into account, TEVA scores 4 out of 10 in our fundamental rating. TEVA was compared to 197 industry peers in the Pharmaceuticals industry. TEVA has a medium profitability rating, but doesn't score so well on its financial health evaluation. TEVA has a bad growth rate and is valued cheaply.
1. Profitability
1.1 Basic Checks
In the past year TEVA was profitable.
In the past year TEVA had a positive cash flow from operations.
In the past 5 years TEVA reported 4 times negative net income.
TEVA had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
TEVA has a Return On Assets of -3.35%. This is in the better half of the industry: TEVA outperforms 78.28% of its industry peers.
TEVA has a Return On Equity of -20.54%. This is in the better half of the industry: TEVA outperforms 71.72% of its industry peers.
TEVA has a Return On Invested Capital of 10.69%. This is amongst the best in the industry. TEVA outperforms 87.88% of its industry peers.
TEVA had an Average Return On Invested Capital over the past 3 years of 9.12%. This is significantly below the industry average of 42.34%.
The last Return On Invested Capital (10.69%) for TEVA is above the 3 year average (9.12%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.35% | ||
| ROE | -20.54% | ||
| ROIC | 10.69% |
ROA(3y)-3.67%
ROA(5y)-3.6%
ROE(3y)-23.1%
ROE(5y)-21.01%
ROIC(3y)9.12%
ROIC(5y)8.26%
1.3 Margins
TEVA has a Operating Margin of 22.19%. This is amongst the best in the industry. TEVA outperforms 88.89% of its industry peers.
TEVA's Operating Margin has improved in the last couple of years.
Looking at the Gross Margin, with a value of 50.49%, TEVA is in the better half of the industry, outperforming 63.13% of the companies in the same industry.
In the last couple of years the Gross Margin of TEVA has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 22.19% | ||
| PM (TTM) | N/A | ||
| GM | 50.49% |
OM growth 3Y0.25%
OM growth 5Y5.91%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.4%
GM growth 5Y2.35%
2. Health
2.1 Basic Checks
TEVA has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
TEVA has more shares outstanding than it did 1 year ago.
TEVA has more shares outstanding than it did 5 years ago.
The debt/assets ratio for TEVA has been reduced compared to a year ago.
2.2 Solvency
The Debt to FCF ratio of TEVA is 21.74, which is on the high side as it means it would take TEVA, 21.74 years of fcf income to pay off all of its debts.
With a decent Debt to FCF ratio value of 21.74, TEVA is doing good in the industry, outperforming 77.78% of the companies in the same industry.
TEVA has a Debt/Equity ratio of 2.59. This is a high value indicating a heavy dependency on external financing.
TEVA has a worse Debt to Equity ratio (2.59) than 77.27% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.59 | ||
| Debt/FCF | 21.74 | ||
| Altman-Z | N/A |
ROIC/WACC1.43
WACC7.49%
2.3 Liquidity
A Current Ratio of 1.03 indicates that TEVA should not have too much problems paying its short term obligations.
With a Current ratio value of 1.03, TEVA is not doing good in the industry: 79.80% of the companies in the same industry are doing better.
A Quick Ratio of 0.74 indicates that TEVA may have some problems paying its short term obligations.
TEVA has a worse Quick ratio (0.74) than 83.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.03 | ||
| Quick Ratio | 0.74 |
3. Growth
3.1 Past
TEVA shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -4.17%.
Measured over the past years, TEVA shows a decrease in Earnings Per Share. The EPS has been decreasing by -1.18% on average per year.
Looking at the last year, TEVA shows a small growth in Revenue. The Revenue has grown by 3.82% in the last year.
Measured over the past years, TEVA shows a decrease in Revenue. The Revenue has been decreasing by -0.41% on average per year.
EPS 1Y (TTM)-4.17%
EPS 3Y-1.18%
EPS 5YN/A
EPS Q2Q%8.33%
Revenue 1Y (TTM)3.82%
Revenue growth 3Y1.38%
Revenue growth 5Y-0.41%
Sales Q2Q%1.89%
3.2 Future
The Earnings Per Share is expected to grow by 6.08% on average over the next years.
The Revenue is expected to grow by 2.12% on average over the next years.
EPS Next Y4.61%
EPS Next 2Y3.56%
EPS Next 3Y6.08%
EPS Next 5YN/A
Revenue Next Year4.36%
Revenue Next 2Y2.16%
Revenue Next 3Y2.12%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 6.76, the valuation of TEVA can be described as very cheap.
94.44% of the companies in the same industry are more expensive than TEVA, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of TEVA to the average of the S&P500 Index (25.91), we can say TEVA is valued rather cheaply.
With a Price/Forward Earnings ratio of 6.40, the valuation of TEVA can be described as very cheap.
Based on the Price/Forward Earnings ratio, TEVA is valued cheaply inside the industry as 93.43% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 21.77. TEVA is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.76 | ||
| Fwd PE | 6.4 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, TEVA is valued cheaply inside the industry as 88.38% of the companies are valued more expensively.
TEVA's Price/Free Cash Flow ratio is rather cheap when compared to the industry. TEVA is cheaper than 81.31% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 25.39 | ||
| EV/EBITDA | 7.29 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
TEVA has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)1.47
PEG (5Y)N/A
EPS Next 2Y3.56%
EPS Next 3Y6.08%
5. Dividend
5.1 Amount
No dividends for TEVA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
16.96
+0.02 (+0.12%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners6.89%
Inst Owner Change8%
Ins Owners0.54%
Ins Owner Change4.01%
Market Cap19.45B
Analysts42.22
Price Target0.05 (-99.71%)
Short Float %2.49%
Short Ratio2.2
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.93%
Min EPS beat(2)2.01%
Max EPS beat(2)5.84%
EPS beat(4)4
Avg EPS beat(4)3.95%
Min EPS beat(4)2.01%
Max EPS beat(4)5.84%
EPS beat(8)6
Avg EPS beat(8)4.67%
EPS beat(12)7
Avg EPS beat(12)0.17%
EPS beat(16)8
Avg EPS beat(16)-1.4%
Revenue beat(2)1
Avg Revenue beat(2)-2.03%
Min Revenue beat(2)-4.68%
Max Revenue beat(2)0.62%
Revenue beat(4)3
Avg Revenue beat(4)-0.15%
Min Revenue beat(4)-4.68%
Max Revenue beat(4)2.63%
Revenue beat(8)6
Avg Revenue beat(8)1.6%
Revenue beat(12)6
Avg Revenue beat(12)-0.3%
Revenue beat(16)6
Avg Revenue beat(16)-1.79%
PT rev (1m)2.41%
PT rev (3m)-24.82%
EPS NQ rev (1m)-3.34%
EPS NQ rev (3m)-3.72%
EPS NY rev (1m)0.36%
EPS NY rev (3m)-0.14%
Revenue NQ rev (1m)-1.13%
Revenue NQ rev (3m)-0.25%
Revenue NY rev (1m)-0.57%
Revenue NY rev (3m)0.37%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.76 | ||
| Fwd PE | 6.4 | ||
| P/S | 1.17 | ||
| P/FCF | 25.39 | ||
| P/OCF | 15.35 | ||
| P/B | 3.11 | ||
| P/tB | N/A | ||
| EV/EBITDA | 7.29 |
EPS(TTM)2.51
EY14.8%
EPS(NY)2.65
Fwd EY15.62%
FCF(TTM)0.67
FCFY3.94%
OCF(TTM)1.1
OCFY6.51%
SpS14.49
BVpS5.46
TBVpS-11.69
PEG (NY)1.47
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.35% | ||
| ROE | -20.54% | ||
| ROCE | 13.53% | ||
| ROIC | 10.69% | ||
| ROICexc | 11.4% | ||
| ROICexgc | 49.41% | ||
| OM | 22.19% | ||
| PM (TTM) | N/A | ||
| GM | 50.49% | ||
| FCFM | 4.61% |
ROA(3y)-3.67%
ROA(5y)-3.6%
ROE(3y)-23.1%
ROE(5y)-21.01%
ROIC(3y)9.12%
ROIC(5y)8.26%
ROICexc(3y)10.21%
ROICexc(5y)9.09%
ROICexgc(3y)56.98%
ROICexgc(5y)49.9%
ROCE(3y)11.55%
ROCE(5y)10.49%
ROICexcg growth 3Y25.78%
ROICexcg growth 5Y17.24%
ROICexc growth 3Y15.91%
ROICexc growth 5Y18.91%
OM growth 3Y0.25%
OM growth 5Y5.91%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.4%
GM growth 5Y2.35%
F-Score4
Asset Turnover0.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.59 | ||
| Debt/FCF | 21.74 | ||
| Debt/EBITDA | 3.44 | ||
| Cap/Depr | 48.59% | ||
| Cap/Sales | 3.02% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 26.85% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.03 | ||
| Quick Ratio | 0.74 | ||
| Altman-Z | N/A |
F-Score4
WACC7.49%
ROIC/WACC1.43
Cap/Depr(3y)44.85%
Cap/Depr(5y)42.78%
Cap/Sales(3y)3.33%
Cap/Sales(5y)3.4%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-4.17%
EPS 3Y-1.18%
EPS 5YN/A
EPS Q2Q%8.33%
EPS Next Y4.61%
EPS Next 2Y3.56%
EPS Next 3Y6.08%
EPS Next 5YN/A
Revenue 1Y (TTM)3.82%
Revenue growth 3Y1.38%
Revenue growth 5Y-0.41%
Sales Q2Q%1.89%
Revenue Next Year4.36%
Revenue Next 2Y2.16%
Revenue Next 3Y2.12%
Revenue Next 5YN/A
EBIT growth 1Y1.35%
EBIT growth 3Y1.63%
EBIT growth 5Y5.48%
EBIT Next Year16.85%
EBIT Next 3Y9.19%
EBIT Next 5YN/A
FCF growth 1Y-20.54%
FCF growth 3Y46.96%
FCF growth 5Y27.42%
OCF growth 1Y-15.19%
OCF growth 3Y16.04%
OCF growth 5Y10.76%